Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 08:20pm CEST

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/10 MYLAN : and Biocon Present Clinical Data on Insulin Glargine at the American Dia..
06/07 MYLAN : to Present at Goldman Sachs 38th Annual Global Healthcare Conference
06/07 Mylan defends chairman to ISS ahead of June 22 investor vote
06/06 JOHN HENDRICKSON : Drugmaker Perrigo says CEO Hendrickson plans to retire
06/05 MYLAN NV : Featured Company News - Mylan Launches Two New Generic Drugs: Generic..
06/02 MYLAN : Launches Generic Azilect® Tablets
06/02 MYLAN : Launches Generic Reclast® Injection
05/23 MYLAN : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefe..
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More news
Sector news : Pharmaceuticals - NEC
07:35pDJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close